Drug intelligence / Profile preview

PfCS102

Development stage: Phase 2
Lead developer: Swiss Tropical and Public Health Institute
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PfCS102 is a synthetic peptide vaccine candidate based on a peptide spanning the C-terminal region of Plasmodium falciparum circumsporozoite protein. It was developed as a potential vaccine against the pre-erythrocytic stage of malaria. Clinical trials have shown that PfCS102 is safe and highly immunogenic, capable of inducing both antibody responses and T-cell mediated immunity in healthy volunteers.

Other names: Malaria Vaccine PfCS 102

Targets

MHC II (Major histocompatibility complex class II receptor)

Beyond the preview

Go deeper on PfCS102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PfCS102.

Explore the full profile